Pharmacopeia, Inc. announced that Schering-Plough Corporation has initiated human trials of a compound discovered through collaboration between the companies. The initiation of this trial for a respiratory indication triggers a milestone payment to Pharmacopeia as part of its agreement with Schering-Plough. Pharmacopeia is also entitled to royalties on commercial sales of products, which result from this collaboration.

"We are delighted to see the tangible evidence of our successful collaboration with Schering-Plough. We greatly value Schering-Plough's commitment to Pharmacopeia and our joint programs," said Joseph Mollica, PhD, chairman and CEO of Pharmacopeia. "This is the third time in the past year that a human clinical trial milestone has been achieved by one of our collaborators for a compound resulting from a programme conducted in collaboration with Pharmacopeia. This achievement reconfirms the contribution Pharmacopeia makes in augmenting our partners' drug development pipelines and advancing their drug discovery initiatives."